Search

Your search keyword '"Schoels, Monika"' showing total 37 results
Start Over Author "Schoels, Monika"
37 results on '"Schoels, Monika"'

1. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Author

Kay, Jonathan, Schoels, Monika M, Dörner, Thomas, Emery, Paul, Kvien, Tore K, Smolen, Josef S, Breedveld, Ferdinand C, Bijlsma, Johannes Wj, Braun, Jürgen, Bykerk, Vivian P, Danese, Silvio, De wit, Maarten Pt, Goncalves, João, Huizinga, Tom Wj, Isaacs, John D, Kavanaugh, Arthur F, Kurki, Pekka, Luger, Thomas A, Müller-ladner, Ulf, Pavelka, Karel, Schellekens, Huub, Strangfeld, Anja, Takeuchi, Tsutomu, Voshaar, Marieke, and Weisman, Michael H

Published
2018
Full Text
View/download PDF

3. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

Author

Stoffer, Michaela A, Schoels, Monika M, Smolen, Josef S, Aletaha, Daniel, Breedveld, Ferdinand C, Burmester, Gerd, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Haraoui, Boulos, Gomez-Reino, Juan, Kvien, Tore K, Nash, Peter, Navarro-Compán, Victoria, Scholte-Voshaar, Marieke, van Vollenhoven, Ronald, van der Heijde, Désirée, and Stamm, Tanja A

Published
2016
Full Text
View/download PDF

4. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Author

Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, and van der Heijde, Desirée

Published
2016
Full Text
View/download PDF

6. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

Author

Smolen, Josef S, Braun, Jürgen, Dougados, Maxime, Emery, Paul, FitzGerald, Oliver, Helliwell, Philip, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Mease, Philip, Olivieri, Ignazio, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, Wit, Martinus de, Baraliakos, Xenofon, Betteridge, Neil, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, Deodhar, Atul, Elewaut, Dirk, Gossec, Laure, Jongkees, Merryn, Maccarone, Mara, Redlich, Kurt, van den Bosch, Filip, Wei, James Cheng-Chung, Winthrop, Kevin, and van der Heijde, Désirée

Published
2014
Full Text
View/download PDF

7. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Author

Schoels, Monika M, van der Heijde, Désirée, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murikama, Miho M, Nishimoto, Norihiro, and Smolen, Josef S

Published
2013
Full Text
View/download PDF

8. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Author

Smolen, Josef S, Schoels, Monika M, Nishimoto, Norihiro, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murakami, Miho, Betteridge, Neil, Bingham, Clifton O, III, Bykerk, Vivian, Choy, Ernest H, Combe, Bernard, Cutolo, Maurizio, Graninger, Winfried, Lanas, Angel, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Ostergaard, Mikkel, Pavelka, Karel, Rubbert-Roth, Andrea, Sattar, Naveed, Scholte-Voshaar, Marieke, Tanaka, Yoshiya, Trauner, Michael, Valentini, Gabriele, Winthrop, Kevin L, de Wit, Maarten, and van der Heijde, Désirée

Published
2013
Full Text
View/download PDF

11. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Author

Smolen, Josef S, Landewé, Robert, Breedveld, Ferdinand C, Dougados, Maxime, Emery, Paul, Gaujoux-Viala, Cecile, Gorter, Simone, Knevel, Rachel, Nam, Jackie, Schoels, Monika, Aletaha, Daniel, Buch, Maya, Gossec, Laure, Huizinga, Tom, Bijlsma, Johannes W, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, Gabay, Cem, Gomez-Reino, Juan, Kouloumas, Marios, Kvien, Tore K, Martin-Mola, Emilio, McInnes, Iain, Pavelka, Karel, van Riel, Piet, Scholte, Marieke, Scott, David L, Sokka, Tuulikki, Valesini, Guido, van Vollenhoven, Ronald, Winthrop, Kevin L, Wong, John, Zink, Angela, and van der Heijde, Désirée

Published
2010
Full Text
View/download PDF

13. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search

Author

Schoels, Monika, Knevel, Rachel, Aletaha, Daniel, Bijlsma, Johannes W, Breedveld, Ferdinand C, Boumpas, Dimitrios T, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, Dougados, Maxime, Emery, Paul, van der Heijde, Desirée, Huizinga, Tom W, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, Martin-Mola, Emilio, Montecucco, Carlomaurizio, de Wit, Maarten, and Smolen, Josef S

Published
2010
Full Text
View/download PDF

14. Treating rheumatoid arthritis to target: recommendations of an international task force

Author

Smolen, Josef S, Aletaha, Daniel, Bijlsma, Johannes W, Breedveld, Ferdinand C, Boumpas, Dimitrios, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, de Wit, Maarten, Dougados, Maxime, Emery, Paul, Gibofsky, Alan, Gomez-Reino, Juan Jesus, Haraoui, Boulos, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, McInnes, Iain, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Schoels, Monika, and van der Heijde, Desirée

Published
2010
Full Text
View/download PDF

19. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Author

Smolen, Josef S., Breedveld, Ferdinand C., Burmester, Gerd R., Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K., Navarro-Compán, M. Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J., Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G., Vollenhoven, Ronald van, Wit, Martinus de, and Heijde, Desirée van der

Subjects
ddc:610
Abstract

Background Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. Objective To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. Methods A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. Results The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1–3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the disease, especially comorbidity and shared decision-making with the patient. Levels of evidence had increased for many items compared with the 2010 recommendations, and levels of agreement were very high for most of the individual recommendations (≥9/10). Conclusions The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.

Published
2015

20. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, van der Heijde, Desirée, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, and van der Heijde, Desirée

Abstract

BACKGROUND: Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights. OBJECTIVE: To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion. METHODS: A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived. RESULTS: The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for particular aspects of the di

Published
2016

21. Treating rheumatoid arthritis to target:2014 update of the recommendations of an international task force

Author

Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, van der Heijde, Desirée, Smolen, Josef S, Breedveld, Ferdinand C, Burmester, Gerd R, Bykerk, Vivian, Dougados, Maxime, Emery, Paul, Kvien, Tore K, Navarro-Compán, M Victoria, Oliver, Susan, Schoels, Monika, Scholte-Voshaar, Marieke, Stamm, Tanja, Stoffer, Michaela, Takeuchi, Tsutomu, Aletaha, Daniel, Andreu, Jose Louis, Aringer, Martin, Bergman, Martin, Betteridge, Neil, Bijlsma, Hans, Burkhardt, Harald, Cardiel, Mario, Combe, Bernard, Durez, Patrick, Fonseca, Joao Eurico, Gibofsky, Alan, Gomez-Reino, Juan J, Graninger, Winfried, Hannonen, Pekka, Haraoui, Boulos, Kouloumas, Marios, Landewe, Robert, Martin-Mola, Emilio, Nash, Peter, Ostergaard, Mikkel, Östör, Andrew, Richards, Pam, Sokka-Isler, Tuulikki, Thorne, Carter, Tzioufas, Athanasios G, van Vollenhoven, Ronald, de Wit, Martinus, and van der Heijde, Desirée

Abstract

BACKGROUND: Reaching the therapeutic target of remission or low-disease activity has improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target recommendations, formulated in 2010, have provided a basis for implementation of a strategic approach towards this therapeutic goal in routine clinical practice, but these recommendations need to be re-evaluated for appropriateness and practicability in the light of new insights.OBJECTIVE: To update the 2010 treat-to-target recommendations based on systematic literature reviews (SLR) and expert opinion.METHODS: A task force of rheumatologists, patients and a nurse specialist assessed the SLR results and evaluated the individual items of the 2010 recommendations accordingly, reformulating many of the items. These were subsequently discussed, amended and voted upon by >40 experts, including 5 patients, from various regions of the world. Levels of evidence, strengths of recommendations and levels of agreement were derived.RESULTS: The update resulted in 4 overarching principles and 10 recommendations. The previous recommendations were partly adapted and their order changed as deemed appropriate in terms of importance in the view of the experts. The SLR had now provided also data for the effectiveness of targeting low-disease activity or remission in established rather than only early disease. The role of comorbidities, including their potential to preclude treatment intensification, was highlighted more strongly than before. The treatment aim was again defined as remission with low-disease activity being an alternative goal especially in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with according therapeutic adaptations to reach the desired state was recommended. Follow-up examinations ought to employ composite measures of disease activity that include joint counts. Additional items provide further details for part

Published
2016

22. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data.

Author

Leuchten, Nicolai, Hoyer, Annika, Brinks, Ralph, Schoels, Monika, Schneider, Matthias, Smolen, Josef, Johnson, Sindhu R., Daikh, David, Dörner, Thomas, Aringer, Martin, Bertsias, George, the Systemic Lupus Erythematosus Classification Criteria Steering Committee, and Systemic Lupus Erythematosus Classification Criteria Steering Committee

Abstract

Objective: To review the published literature on the performance of indirect immunofluorescence (IIF)-HEp-2 antinuclear antibody (ANA) testing for classification of systemic lupus erythematosus (SLE).Methods: A systematic literature search was conducted in the Medline, Embase, and Cochrane databases for articles published between January 1990 and October 2015. The research question was structured according to Population, Intervention, Comparator, Outcome (PICO) format rules, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were followed where appropriate. Meta-regression analysis for diagnostic tests was performed, using the ANA titer as independent variable, while sensitivity and specificity were dependent variables.Results: Of 4,483 publications screened, 62 matched the eligibility criteria, and another 2 articles were identified through reference analysis. The included studies comprised 13,080 SLE patients in total, of whom 12,542 (95.9%) were reported to be IIF-ANA positive at various titers. For ANA at titers of 1:40, 1:80, 1:160, and 1:320, meta-regression gave sensitivity values of 98.4% (95% confidence interval [95% CI] 97.6-99.0%), 97.8% (95% CI 96.8-98.5%), 95.8% (95% CI 94.1-97.1%), and 86.0% (95% CI 77.0-91.9%), respectively. The corresponding specificities were 66.9% (95% CI 57.8-74.9%), 74.7% (95% CI 66.7-81.3%), 86.2% (95% CI 80.4-90.5%), and 96.6% (95% CI 93.9-98.1%), respectively.Conclusion: The results of this systematic literature review and meta-regression confirm that IIF-ANAs have high sensitivity for SLE. ANAs at a titer of 1:80 have sufficiently high sensitivity to be considered as an entry criterion for SLE classification criteria, i.e., formally test other classification criteria for SLE only if ANAs of at least 1:80 have been found. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

24. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

Author

Stoffer, Michaela A, primary, Schoels, Monika M, additional, Smolen, Josef S, additional, Aletaha, Daniel, additional, Breedveld, Ferdinand C, additional, Burmester, Gerd, additional, Bykerk, Vivian, additional, Dougados, Maxime, additional, Emery, Paul, additional, Haraoui, Boulos, additional, Gomez-Reino, Juan, additional, Kvien, Tore K, additional, Nash, Peter, additional, Navarro-Compán, Victoria, additional, Scholte-Voshaar, Marieke, additional, van Vollenhoven, Ronald, additional, van der Heijde, Désirée, additional, and Stamm, Tanja A, additional

Published
2015
Full Text
View/download PDF

25. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

Author

Smolen, Josef S, primary, Breedveld, Ferdinand C, additional, Burmester, Gerd R, additional, Bykerk, Vivian, additional, Dougados, Maxime, additional, Emery, Paul, additional, Kvien, Tore K, additional, Navarro-Compán, M Victoria, additional, Oliver, Susan, additional, Schoels, Monika, additional, Scholte-Voshaar, Marieke, additional, Stamm, Tanja, additional, Stoffer, Michaela, additional, Takeuchi, Tsutomu, additional, Aletaha, Daniel, additional, Andreu, Jose Louis, additional, Aringer, Martin, additional, Bergman, Martin, additional, Betteridge, Neil, additional, Bijlsma, Hans, additional, Burkhardt, Harald, additional, Cardiel, Mario, additional, Combe, Bernard, additional, Durez, Patrick, additional, Fonseca, Joao Eurico, additional, Gibofsky, Alan, additional, Gomez-Reino, Juan J, additional, Graninger, Winfried, additional, Hannonen, Pekka, additional, Haraoui, Boulos, additional, Kouloumas, Marios, additional, Landewe, Robert, additional, Martin-Mola, Emilio, additional, Nash, Peter, additional, Ostergaard, Mikkel, additional, Östör, Andrew, additional, Richards, Pam, additional, Sokka-Isler, Tuulikki, additional, Thorne, Carter, additional, Tzioufas, Athanasios G, additional, van Vollenhoven, Ronald, additional, de Wit, Martinus, additional, and van der Heijde, Desirée, additional

Published
2015
Full Text
View/download PDF

26. Treating rheumatoid arthritis to target : recommendations of an international task force.

Author

UCL - (SLuc) Service de rhumatologie, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, Smolen, Josef S, Aletaha, Daniel, Bijlsma, Johannes W J, Breedveld, Ferdinand C, Boumpas, Dimitrios, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, de Wit, Maarten, Dougados, Maxime, Emery, Paul, Gibofsky, Alan, Gomez-Reino, Juan Jesus, Haraoui, Boulos, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, McInnes, Iain, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Schoels, Monika, van der Heijde, Désirée, van der Heijde, Desirée, Durez, Patrick, UCL - (SLuc) Service de rhumatologie, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, Smolen, Josef S, Aletaha, Daniel, Bijlsma, Johannes W J, Breedveld, Ferdinand C, Boumpas, Dimitrios, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, de Wit, Maarten, Dougados, Maxime, Emery, Paul, Gibofsky, Alan, Gomez-Reino, Juan Jesus, Haraoui, Boulos, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, McInnes, Iain, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Schoels, Monika, van der Heijde, Désirée, van der Heijde, Desirée, and Durez, Patrick

Abstract

Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA).

Published
2010

27. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

Author

Smolen, Josef S, primary, Braun, Jürgen, additional, Dougados, Maxime, additional, Emery, Paul, additional, FitzGerald, Oliver, additional, Helliwell, Philip, additional, Kavanaugh, Arthur, additional, Kvien, Tore K, additional, Landewé, Robert, additional, Luger, Thomas, additional, Mease, Philip, additional, Olivieri, Ignazio, additional, Reveille, John, additional, Ritchlin, Christopher, additional, Rudwaleit, Martin, additional, Schoels, Monika, additional, Sieper, Joachim, additional, Wit, Martinus de, additional, Baraliakos, Xenofon, additional, Betteridge, Neil, additional, Burgos-Vargas, Ruben, additional, Collantes-Estevez, Eduardo, additional, Deodhar, Atul, additional, Elewaut, Dirk, additional, Gossec, Laure, additional, Jongkees, Merryn, additional, Maccarone, Mara, additional, Redlich, Kurt, additional, van den Bosch, Filip, additional, Wei, James Cheng-Chung, additional, Winthrop, Kevin, additional, and van der Heijde, Désirée, additional

Published
2013
Full Text
View/download PDF

29. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Author

Smolen, Josef S, primary, Schoels, Monika M, additional, Nishimoto, Norihiro, additional, Breedveld, Ferdinand C, additional, Burmester, Gerd R, additional, Dougados, Maxime, additional, Emery, Paul, additional, Ferraccioli, Gianfranco, additional, Gabay, Cem, additional, Gibofsky, Allan, additional, Gomez-Reino, Juan Jesus, additional, Jones, Graeme, additional, Kvien, Tore K, additional, Murakami, Miho, additional, Betteridge, Neil, additional, Bingham, Clifton O, additional, Bykerk, Vivian, additional, Choy, Ernest H, additional, Combe, Bernard, additional, Cutolo, Maurizio, additional, Graninger, Winfried, additional, Lanas, Angel, additional, Martin-Mola, Emilio, additional, Montecucco, Carlomaurizio, additional, Ostergaard, Mikkel, additional, Pavelka, Karel, additional, Rubbert-Roth, Andrea, additional, Sattar, Naveed, additional, Scholte-Voshaar, Marieke, additional, Tanaka, Yoshiya, additional, Trauner, Michael, additional, Valentini, Gabriele, additional, Winthrop, Kevin L, additional, de Wit, Maarten, additional, and van der Heijde, Désirée, additional

Published
2012
Full Text
View/download PDF

30. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Author

Schoels, Monika M, primary, van der Heijde, Désirée, additional, Breedveld, Ferdinand C, additional, Burmester, Gerd R, additional, Dougados, Maxime, additional, Emery, Paul, additional, Ferraccioli, Gianfranco, additional, Gabay, Cem, additional, Gibofsky, Allan, additional, Gomez-Reino, Juan Jesus, additional, Jones, Graeme, additional, Kvien, Tore K, additional, Murikama, Miho M, additional, Nishimoto, Norihiro, additional, and Smolen, Josef S, additional

Published
2012
Full Text
View/download PDF

32. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008

Author

Schoels, Monika, primary, Aletaha, Daniel, additional, Smolen, Josef S, additional, Bijlsma, Johannes W J, additional, Burmester, Gerd, additional, Breedveld, Ferdinand C, additional, Cutolo, Maurizio, additional, Combe, Bernard, additional, Dougados, Maxime, additional, Emery, Paul, additional, Kalden, Joachim, additional, Keystone, Edward C, additional, Kvien, Tore K, additional, Martin-Mola, Emilio, additional, Montecucco, Carlomaurizio, additional, and De Wit, Maarten, additional

Published
2009
Full Text
View/download PDF

36. Treating rheumatoid arthritis to target: Recommendations of an international task force

Author

Smolen, Josef S, Aletaha, Daniel, Bijlsma, Johannes W J, Breedveld, Ferdinand C, Boumpas, Dimitrios, Burmester, Gerd, Combe, Bernard, Cutolo, Maurizio, de Wit, Maarten, Dougados, Maxime, Emery, Paul, Gibofsky, Alan, Gomez-Reino, Juan Jesus, Haraoui, Boulos, Kalden, Joachim, Keystone, Edward C, Kvien, Tore K, McInnes, Iain, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Schoels, Monika, van der Heijde, Désirée, van der Heijde, Desirée, Durez, Patrick, UCL - (SLuc) Service de rhumatologie, and UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales

Subjects
medicine.medical_specialty, Immunology, Treatment outcome, Arthritis, Recommendations, Severity of Illness Index, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, Remission induction, Arthritis, Rheumatoid - drug therapy, Rheumatology, Diabetes mellitus, Severity of illness, medicine, Humans, Immunology and Allergy, Evidence-Based Medicine - methods, Intensive care medicine, Antirheumatic Agents - therapeutic use, Evidence-Based Medicine, business.industry, Task force, Remission Induction, medicine.disease, Connective tissue disease, Treatment Outcome, Antirheumatic Agents, Rheumatoid arthritis, Physical therapy, business, reporting disease-activity c-reactive protein eular/acr collaborative recommendations modifying antirheumatic drugs randomized controlled-trial clinical-trials radiologic damage follow-up methotrexate monotherapy treatment strategies, Algorithms
Abstract

Background Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA). Objective To develop recommendations for achieving optimal therapeutic outcomes in RA. Methods A task force of rheumatologists and a patient developed a set of recommendations on the basis of evidence derived from a systematic literature review and expert opinion; these were subsequently discussed, amended and voted upon by >60 experts from various regions of the world in a Delphi-like procedure. Levels of evidence, strength of recommendations and levels of agreement were derived. Results The treat-to-target activity resulted in 10 recommendations. The treatment aim was defined as remission with low disease activity being an alternative goal in patients with long-standing disease. Regular follow-up (every 1-3 months during active disease) with appropriate therapeutic adaptation to reach the desired state within 3 to a maximum of 6 months was recommended. Follow-up examinations ought to employ composite measures of disease activity which include joint counts. Additional items provide further details for particular aspects of the disease. Levels of agreement were very high for many of these recommendations (>= 9/10). Conclusion The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.

37. Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review.

Author

Smolen JS, Schoels M, and Aletaha D

Subjects
Arthralgia diagnosis, Arthralgia physiopathology, Arthritis, Psoriatic blood, Arthritis, Psoriatic immunology, Arthritis, Psoriatic physiopathology, Biomarkers blood, C-Reactive Protein analysis, Humans, Inflammation Mediators blood, Joints pathology, Joints physiopathology, Pain Measurement, Predictive Value of Tests, Reproducibility of Results, Severity of Illness Index, Surveys and Questionnaires, Treatment Outcome, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic therapy, Health Status, Health Status Indicators
Abstract

In this review we provide reasons to use joint specific composite measures of disease activity for psoriatic arthritis (PsA) rather than composite scores that combine several manifestations of psoriatic disease, including skin involvement. Based on a principal component analysis, which, indeed, excluded skin involvement as a major factor in PsA, the Disease Activity index for PSoriatic Arthritis (DAPSA) was validated using clinical trial and observational data. Further, disease activity states and response criteria were recently defined. The DAPSA is simply calculated by summing swollen + tender joint counts + patient pain + patient global assessments + CRP, using 66/68 joint counts. DAPSA has meanwhile been validated in other studies and has shown to have a very high level of validity, also when compared with joint sonography. Thus, DAPSA is useful in clinical practice, clinical trials and observational studies.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results